GOVX - GeoVax Labs, Inc. Stock Price, Fair Value and News

$0.40+0.03 (+8.11%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

GOVX Price Action

Last 30 days

-29.8%

Last 90 days

-45.9%

Trailing 12 Months

-83.0%

GOVX RSI Chart

GOVX Valuation

Market Cap

11.9M

Price/Earnings (Trailing)

-0.47

Price/Sales (Trailing)

3.54

Price/Free Cashflow

-0.49

GOVX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

GOVX Fundamentals

GOVX Revenue

Revenue (TTM)

3.4M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

GOVX Earnings

Earnings (TTM)

-25.3M

Earnings Growth (Yr)

-8.66%

Earnings Growth (Qtr)

-17.68%

GOVX Profitability

Return on Equity

-515.77%

Return on Assets

-375.99%

Free Cashflow Yield

-204.45%

GOVX Investor Care

Shares Dilution (1Y)

214.81%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	5.6M	6.1M	3.4M	0
2024	0	300.7K	3.1M	4.0M
2022	356.6K	276.9K	246.5K	81.5K
2021	1.2M	857.2K	472.2K	385.5K
2020	1.5M	1.8M	1.8M	1.8M
2019	1.1M	1.2M	1.2M	1.2M
2018	1.0M	742.0K	843.3K	963.2K
2017	1.1M	1.3M	1.1M	1.1M
2016	372.3K	467.1K	814.0K	828.9K
2015	829.0K	720.1K	491.1K	428.1K
2014	1.8M	1.5M	834.6K	883.0K
2013	2.6M	2.3M	2.7M	2.4M
2012	4.9M	3.8M	3.2M	2.7M
2011	4.7M	4.8M	4.9M	4.9M
2010	0	4.2M	4.7M	5.2M
2009	0	0	0	3.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About GeoVax Labs, Inc.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

CEO	Mr. David Alan Dodd
WEBSITE	geovax.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	14

GeoVax Labs, Inc. Frequently Asked Questions

What is the ticker symbol for GeoVax Labs, Inc.? What does GOVX stand for in stocks?

GOVX is the stock ticker symbol of GeoVax Labs, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of GeoVax Labs, Inc. (GOVX)?

As of Wed Dec 03 2025, market cap of GeoVax Labs, Inc. is 11.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GOVX stock?

You can check GOVX's fair value in chart for subscribers.

Is GeoVax Labs, Inc. a good stock to buy?

The fair value guage provides a quick view whether GOVX is over valued or under valued. Whether GeoVax Labs, Inc. is cheap or expensive depends on the assumptions which impact GeoVax Labs, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GOVX.

What is GeoVax Labs, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, GOVX's PE ratio (Price to Earnings) is -0.47 and Price to Sales (PS) ratio is 3.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GOVX PE ratio will change depending on the future growth rate expectations of investors.